Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit ...

Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and ...

McDonald’s Corp. shares slipped on Tuesday after Redburn Atlantic gave the burger chain its sole sell rating, saying shifting ...

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.